Last updated: April 26, 2026
AU2007237903: What Is Claimed, What the Scope Covers, and How It Fits the Australia Drug Patent Landscape
AU2007237903 is an Australian patent application that maps to a drug-focused IP position with definable claim scope and a traceable landscape across priority and related family filings. The Australian claim set determines the enforceable scope in Australia, while the family documents (priority and corresponding filings in other jurisdictions) typically define the technical boundaries that prosecution history and claim construction later tighten.
What is AU2007237903 and what is its claim center of gravity?
AU2007237903 is an Australian patent application published in the 2007 publication cycle (application number format “AU2007…”) and belongs to a drug invention family tied to a specific active ingredient and its pharmaceutical use. In practice for drug families of this era, the enforceable core typically falls into one or more of these buckets:
- Product claims covering a compound (or a salt/solvate), sometimes defined by a Markush structure or by specific chemical entities.
- Composition claims covering formulations (pharmaceutical compositions, dosage forms, excipient sets).
- Method-of-use claims for treatment or prophylaxis of one or more therapeutic indications.
For AU2007237903 specifically, the effective scope in Australia is determined by the independent claim(s) and how dependent claims narrow or broaden the drug definition (compound identity), the formulation definition (dosage form and components), and the use definition (disease or patient populations).
What does the claim set typically require in Australia drug cases like this?
Australian drug claim drafting in the 2000s tends to follow a predictable architecture that drives claim construction:
- Drug identity: claims either name a defined chemical entity, or define a class via substituent patterns, or define a salt/solvate of a named compound.
- Pharmaceutical formulation: claims often require at least one pharmaceutically acceptable excipient and sometimes constrain dosage form (tablet, capsule, solution) or release profile.
- Therapeutic use: claims typically tie to a target disease state and include dosing or administration parameters only when those parameters are central to novelty and inventive step.
This architecture matters for landscape mapping because it dictates how competitors attempt to design around: changing salt form, changing formulation composition, changing administration route, or shifting to adjacent therapeutic indications that are outside the defined use.
How does AU2007237903 position in the patent landscape?
The patent landscape for an AU drug application is assessed by triangulating four layers:
1) Family linkage (priority and related jurisdictions)
AU applications generally have:
- a priority filing date that anchors novelty and inventorship analysis,
- corresponding filings in key markets (US, EP, CA, JP, CN, KR) that show whether the invention was globally pursued and how claims evolved.
Landscape use:
- If overseas prosecution narrowed claims around compound definition or dosing, the narrower elements often reappear in AU.
- If foreign patents granted broad structural claims but were later constrained, AU scope often matches the allowed language.
2) Citation and prosecution signals
Australian examiners (IP Australia) and patent databases show:
- prior art citations,
- claim rejections and amendments (where available),
- whether the application depended on a specific technical contribution such as a new salt form, improved stability, or a new use.
Landscape use:
- The more the allowance depends on a specific technical feature, the more that feature becomes the claim “pressure point” for design-around.
3) Post-grant enforceability effects
In Australia, enforceability depends on:
- claim clarity,
- sufficiency,
- novelty and inventive step at the claim level.
Landscape use:
- If claims survive only because of narrow dependent limitations, that narrows the real-world freedom-to-operate (FTO).
4) Regulatory interplay (PBS and ARTG listings)
For drug families, market impact often correlates with:
- the Australian Register of Therapeutic Goods (ARTG) listing for the active ingredient and dosage forms,
- Pharmaceutical Benefits Scheme (PBS) listing and any concessional product evolution.
Landscape use:
- Formulation-specific claims can matter for follow-on products that target particular dosage forms on ARTG.
What claim categories should be evaluated for AU2007237903 in Australia?
For business and infringement/FTO purposes, AU2007237903 should be analyzed across these claim categories (even when the exact wording must be checked claim-by-claim):
- Compound or salt/solvate claims
- Scope hinges on whether the claim is limited to a named salt/solvate versus a broader definition.
- Pharmaceutical composition claims
- Scope hinges on excipient limitations, dosage form, and whether the claim captures “any formulation” or only enumerated embodiments.
- Method-of-treatment claims
- Scope hinges on disease definition, patient subgroup definition, and whether the claim requires specific administration/dosing.
- Combination therapy claims (if present)
- Scope hinges on the second active, dosing ratios, and regimen definition.
In most drug portfolios, the most commercially meaningful value often sits in the method-of-use and composition claim sets, because those drive how generics and biosimilar-like competitors can (or cannot) market adjacent products.
What design-arounds are typically available against Australian drug claim sets?
Without the exact claim text reproduced here, the practical design-around pathways for Australian drug cases of this type remain consistent:
- Salt/solvate substitution: if claims lock to a specific salt form.
- Formulation redesign: if composition claims constrain excipients or dosage form.
- Route change: if method claims require a defined administration route.
- Indication carve-outs: if claims limit to a specific therapeutic use or patient group.
- Combination regimen changes: if claims require a specified drug partner and regimen.
In landscape work, these are mapped to:
- the competitor’s planned product label,
- ARTG dossier category,
- clinical protocol alignment for dosing and patient inclusion.
How should AU2007237903 be screened against freedom-to-operate (FTO) workflows?
For an investment-grade FTO screen in Australia, the following process typically determines whether AU2007237903 blocks a product:
Step A: Claim-to-product mapping
- Map the active ingredient identity (including salt form) to compound claims.
- Map dosage form and excipients (or key formulation traits) to composition claims.
- Map indication language and dosing/route to use claims.
Step B: Scope compression via dependent claims
- If independent claims are broad but dependent claims narrow, the design-around target becomes the narrowest limitation that actually distinguishes the claimed invention.
Step C: Evidence of invalidity risk (only after claim mapping)
- Novelty/inventive step challenges often depend on specific prior art.
- Sufficiency challenges can depend on whether the patent teaches the invention across the full claim scope.
Step D: Regulatory and marketing alignment
- If a competitor’s label avoids the claimed indication or route, the risk shifts from method-of-use claims to composition/compound claims.
What competitor activity patterns usually show up around such AU drug families?
For drug families from the AU 2007 publication window, the market pattern usually looks like:
- Generics seek composition and method carve-outs.
- Sponsors file follow-on patents on:
- new salts,
- new formulations (e.g., controlled release),
- new indications.
- Claim breadth often narrows through prosecution, creating a patchwork landscape where only certain use cases are protected.
In portfolio terms, AU2007237903 often anchors one layer of protection while later or adjacent filings cover follow-on IP.
What is the practical “value driver” of AU2007237903’s claim scope?
For investors and R&D decision-makers, the value driver is not the publication number; it is whether the claim set:
- protects a specific compound form (salt/solvate) that competitors must replicate,
- protects a specific dosage form/formulation, limiting generic substitution,
- protects a specific indication and dosing/regimen, limiting label-based entry,
- covers combinations that are clinically used and harder to work around.
Those are the levers that translate patent language into market exclusion or licensing leverage.
Key Takeaways
- AU2007237903’s enforceable scope in Australia is defined by its independent claims and tightened by dependent limitations across compound identity, formulation, and method-of-use.
- Landscape impact depends on how claim language translates to product labeling and regulatory dossiers (ARTG/PBS aligned indication, route, and dosage form).
- Design-arounds usually target the same technical pressure points: salt form, formulation constraints, route of administration, indication carve-outs, and combination regimen definitions.
- A defensible FTO posture requires claim-to-product mapping at the limitation level, then checking whether competitors can avoid the narrowest claim elements that give the patent novelty.
FAQs
1) What typically makes an Australian drug patent operationally enforceable?
The independent claim language that clearly and narrowly defines compound/formulation/use, with dependent claims that further specify the novelty-relevant features.
2) Where do companies usually focus for design-around against drug patents?
Salt/solvate selection, excipient and dosage form changes, route of administration shifts, and avoidance of the claimed indication language.
3) How does claim category affect infringement risk?
Compound claims create the broadest barrier to identical active ingredient products; method claims shift risk toward label and clinical protocol alignment; composition claims concentrate risk on formulation and dosage form.
4) Why do family documents matter for Australia scope decisions?
They show the technical boundaries and claim evolution that often inform how the invention was prosecuted and what features survived scrutiny.
5) How do regulatory listings interact with patent scope in Australia?
ARTG and PBS listings drive what indications, dosage forms, and routes the market actually sells, which in turn maps directly to method-of-use and composition claim exposure.
References
[1] IP Australia. “Australian Patent Search.” https://www.ipaustralia.gov.au/
[2] WIPO. “PATENTSCOPE.” https://patentscope.wipo.int/
[3] Espacenet. “European Patent Register and Documentation.” https://worldwide.espacenet.com/
